Index by author

April 01 2012; volume 30 issue 2

A

  1. Anderson, John

    1. How Proven Primary Prevention Can Stop Diabetes
      John Anderson, Meghan Riley and Tekisha Dwan Everette
      Clinical Diabetes 2012 Apr; 30 (2): 76-79. https://doi.org/10.2337/diaclin.30.2.76

B

  1. Blehm, Julie

    1. Use of A1C for Screening and Diagnosis of Type 2 Diabetes in Three Rural Health Care Systems
      Susan Kuntz, Eric L. Johnson, Julie Blehm and Charles C. Hosford
      Clinical Diabetes 2012 Apr; 30 (2): 61-66. https://doi.org/10.2337/diaclin.30.2.61

  2. Brunner, John E.

    1. A New Challenge for Safe Ordering of U-500 Insulin: Electronic Medicine Reconciliation
      John E. Brunner and Guillermo M. Guardia
      Clinical Diabetes 2012 Apr; 30 (2): 70-71. https://doi.org/10.2337/diaclin.30.2.70

C

  1. Clark, Nathaniel G.

    1. Postprandial Blood Glucose, Cardiovascular Events, and All-Cause Mortality: How Do We Use Postprandial Glucose in Clinical Practice?
      Nathaniel G. Clark
      Clinical Diabetes 2012 Apr; 30 (2): 67-69. https://doi.org/10.2337/diaclin.30.2.67

  2. Close, John

    1. The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?
      Lisa S. Rotenstein, Benjamin M. Kozak, Joseph P. Shivers, Mark Yarchoan, John Close and Kelly L. Close
      Clinical Diabetes 2012 Apr; 30 (2): 44-53. https://doi.org/10.2337/diaclin.30.2.44

  3. Close, Kelly L.

    1. The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?
      Lisa S. Rotenstein, Benjamin M. Kozak, Joseph P. Shivers, Mark Yarchoan, John Close and Kelly L. Close
      Clinical Diabetes 2012 Apr; 30 (2): 44-53. https://doi.org/10.2337/diaclin.30.2.44

E

  1. Everette, Tekisha Dwan

    1. How Proven Primary Prevention Can Stop Diabetes
      John Anderson, Meghan Riley and Tekisha Dwan Everette
      Clinical Diabetes 2012 Apr; 30 (2): 76-79. https://doi.org/10.2337/diaclin.30.2.76

F

  1. Farahani, Pendar

    1. A Perspective on Principles of Comparative Cost-Effectiveness Studies for Pharmacotherapy of Chronic Diseases
      Pendar Farahani
      Clinical Diabetes 2012 Apr; 30 (2): 54-60. https://doi.org/10.2337/diaclin.30.2.54

G

  1. Guardia, Guillermo M.

    1. A New Challenge for Safe Ordering of U-500 Insulin: Electronic Medicine Reconciliation
      John E. Brunner and Guillermo M. Guardia
      Clinical Diabetes 2012 Apr; 30 (2): 70-71. https://doi.org/10.2337/diaclin.30.2.70

H

  1. Hosford, Charles C.

    1. Use of A1C for Screening and Diagnosis of Type 2 Diabetes in Three Rural Health Care Systems
      Susan Kuntz, Eric L. Johnson, Julie Blehm and Charles C. Hosford
      Clinical Diabetes 2012 Apr; 30 (2): 61-66. https://doi.org/10.2337/diaclin.30.2.61

J

  1. Johnson, Eric L.

    1. Use of A1C for Screening and Diagnosis of Type 2 Diabetes in Three Rural Health Care Systems
      Susan Kuntz, Eric L. Johnson, Julie Blehm and Charles C. Hosford
      Clinical Diabetes 2012 Apr; 30 (2): 61-66. https://doi.org/10.2337/diaclin.30.2.61

K

  1. Kozak, Benjamin M.

    1. The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?
      Lisa S. Rotenstein, Benjamin M. Kozak, Joseph P. Shivers, Mark Yarchoan, John Close and Kelly L. Close
      Clinical Diabetes 2012 Apr; 30 (2): 44-53. https://doi.org/10.2337/diaclin.30.2.44

  2. Kruger, Davida F.

    1. Diabetes Treatment Options: One Size Does NOT Fit All
      Davida F. Kruger
      Clinical Diabetes 2012 Apr; 30 (2): 41-43. https://doi.org/10.2337/diaclin.30.2.41

  3. Kuntz, Susan

    1. Use of A1C for Screening and Diagnosis of Type 2 Diabetes in Three Rural Health Care Systems
      Susan Kuntz, Eric L. Johnson, Julie Blehm and Charles C. Hosford
      Clinical Diabetes 2012 Apr; 30 (2): 61-66. https://doi.org/10.2337/diaclin.30.2.61

L

  1. Lahiri, Sharon W.

    1. Management of Type 2 Diabetes: What Is the Next Step After Metformin?
      Sharon W. Lahiri
      Clinical Diabetes 2012 Apr; 30 (2): 72-75. https://doi.org/10.2337/diaclin.30.2.72

R

  1. Riley, Meghan

    1. How Proven Primary Prevention Can Stop Diabetes
      John Anderson, Meghan Riley and Tekisha Dwan Everette
      Clinical Diabetes 2012 Apr; 30 (2): 76-79. https://doi.org/10.2337/diaclin.30.2.76

  2. Rotenstein, Lisa S.

    1. The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?
      Lisa S. Rotenstein, Benjamin M. Kozak, Joseph P. Shivers, Mark Yarchoan, John Close and Kelly L. Close
      Clinical Diabetes 2012 Apr; 30 (2): 44-53. https://doi.org/10.2337/diaclin.30.2.44

S

  1. Shivers, Joseph P.

    1. The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?
      Lisa S. Rotenstein, Benjamin M. Kozak, Joseph P. Shivers, Mark Yarchoan, John Close and Kelly L. Close
      Clinical Diabetes 2012 Apr; 30 (2): 44-53. https://doi.org/10.2337/diaclin.30.2.44

V

  1. Valentine, Virginia

    1. Don't Resist Using U-500 Insulin and Pramlintide for Severe Insulin Resistance
      Virginia Valentine
      Clinical Diabetes 2012 Apr; 30 (2): 80-84. https://doi.org/10.2337/diaclin.30.2.80

Y

  1. Yarchoan, Mark

    1. The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?
      Lisa S. Rotenstein, Benjamin M. Kozak, Joseph P. Shivers, Mark Yarchoan, John Close and Kelly L. Close
      Clinical Diabetes 2012 Apr; 30 (2): 44-53. https://doi.org/10.2337/diaclin.30.2.44
Back to top